KPV Peptide: A Research Overview of Structure, Origins, and Published Studies
The KPV peptide is one of the smallest research peptides in common use: just three amino acids. Despite its size, it has a surprisingly specific research history, tied to the melanocortin system and to studies of how short peptides are transported across intestinal cells. This overview summarizes what KPV is, where it comes from, what published research has examined, and what to check when sourcing it for laboratory work. It is written for researchers; it does not make or imply any health or therapeutic claims.
What is the KPV peptide?
KPV is the tripeptide lysine-proline-valine (Lys-Pro-Val). It corresponds to the C-terminal end (residues 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino-acid peptide derived from the precursor protein pro-opiomelanocortin (POMC). Because it is so short, KPV is straightforward to synthesize by standard solid-phase peptide synthesis and has a low molecular weight compared with most research peptides.
| Property | KPV |
|---|---|
| Sequence | Lys-Pro-Val (K-P-V) |
| Length | 3 amino acids (tripeptide) |
| Parent molecule | C-terminal fragment of alpha-MSH (residues 11-13) |
| Typical research form | Lyophilized powder in sealed vials |
Origins: the alpha-MSH connection
Alpha-MSH has been studied for decades as part of the melanocortin system, which signals through a family of melanocortin receptors (MC1R through MC5R). Researchers became interested in whether small fragments of alpha-MSH retain any of the parent molecule’s activity in experimental systems. A major review in Endocrine Reviews summarized the biochemistry of alpha-MSH and related tripeptides, including KPV and the analog K(D)PT, and the in-vitro and in-vivo models in which they had been examined (Brzoska et al., 2008).
For an overview of another regulatory neuropeptide studied in gut, neural and immune research models, see our VIP peptide research overview.
One reason the fragment interests researchers is an open question discussed in that literature: how much of KPV’s activity in a given model depends on classic melanocortin receptor binding versus other mechanisms. That question makes it a useful tool compound when a study needs to separate receptor-dependent from receptor-independent effects.
Published research: PepT1 transport studies
The most frequently cited KPV paper is a 2008 study in Gastroenterology that examined how KPV is taken up by intestinal epithelial cells. The authors reported that KPV is transported by PepT1, a di- and tripeptide transporter expressed in the intestine, and examined its effects in cell and mouse models of intestinal inflammation (Dalmasso et al., 2008).
Later work explored delivery approaches in animal models. For example, a 2017 study in Molecular Therapy described hyaluronic acid-functionalized nanoparticles designed to deliver KPV orally in a mouse colitis model (Xiao et al., 2017). Studies like these are preclinical, conducted in cells and rodents, and their findings should be read as research observations about model systems rather than as evidence of any effect in people.
How researchers typically use KPV in study design
Within the published literature, KPV tends to appear in a few kinds of experiments:
- Transporter studies: as a model substrate for PepT1-mediated uptake of short peptides.
- Fragment-activity comparisons: alongside full-length alpha-MSH or analogs such as K(D)PT, to compare which parts of the molecule drive a response in a given assay.
- Delivery and formulation work: as a cargo for nanoparticle or targeted-delivery systems, where its small size and stability are practical advantages.
- Multi-peptide formulation research: as one component in blends, such as KLOW blend, where researchers need to attribute effects to individual components.
Because KPV is a fragment, many study designs also compare it directly against the parent hormone at matched molar concentrations rather than matched mass. A tripeptide has a far lower molecular weight than alpha-MSH, so equal milligram amounts contain very different numbers of molecules, and mass-matched comparisons can be misleading.
Good practice is to include appropriate controls (vehicle, scrambled-sequence peptide where relevant, and the parent molecule where comparison matters) and to record the exact lot of material used.
Sourcing KPV for research: what to verify
Because KPV is a short, simple peptide, buyers sometimes assume quality is a given. It is not. Short peptides can still carry synthesis impurities, residual counter-ions (for example trifluoroacetate from purification) and moisture. Before using any lot, check that the Certificate of Analysis shows:
- Identity by mass spectrometry matching the expected mass for Lys-Pro-Val.
- Purity by HPLC, ideally with the chromatogram attached.
- A lot number that matches the vial label.
- An independent testing laboratory named on the report.
You can review the reports we publish on our lab testing and COA page and see our KPV 10mg research peptide listing in the shop. For a broader primer on reading these reports, see our guide to interpreting COAs, HPLC purity and mass spectrometry.
Limits of the current evidence
It is worth being precise about what the KPV literature does and does not show. The published work is concentrated in cell culture and rodent models, often from a limited number of research groups, and uses different formulations and delivery methods. Findings in one model do not automatically carry over to another, so any new study should state its model, material source, lot and controls clearly.
Handling and storage in the lab
Like most lyophilized peptides, KPV is commonly stored sealed, cold, dry and protected from light, then reconstituted only when needed. Reconstitution vehicle choice affects how long a solution can be kept and drawn from; our article on bacteriostatic water vs. sterile water for peptide reconstitution explains the trade-offs for lab use.
Frequently Asked Questions
What is KPV?
KPV is the tripeptide lysine-proline-valine, the C-terminal fragment (residues 11-13) of alpha-melanocyte-stimulating hormone. It is sold as a lyophilized research peptide for laboratory use only.
Where does KPV come from?
KPV is derived from the sequence of alpha-MSH, which is processed from the precursor protein pro-opiomelanocortin (POMC). Research peptide KPV is made synthetically, typically by solid-phase peptide synthesis.
What has published research on KPV examined?
Published studies have examined KPV’s uptake by the PepT1 peptide transporter in intestinal cells and its behavior in cell and rodent models, as well as nanoparticle delivery approaches. These are preclinical studies of model systems and do not establish any effect in humans.
What should a KPV certificate of analysis show?
It should show identity by mass spectrometry, purity by HPLC, a lot number matching your vial, and the name of the independent laboratory that ran the tests. A recent report date and a verification ID are additional signs of a well-documented lot.
Research use only. All Pure Tested Peptides products are sold strictly for laboratory research and are not for human or veterinary use. Nothing in this article is medical advice or a claim that any compound diagnoses, treats, cures, or prevents any condition.




Leave a Reply
Want to join the discussion?Feel free to contribute!